Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week phase 3 study of umeclidinium/vilanterol and individual components in COPD
2010-023349-32Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Clinic visit trough FEV1 on Treatment Day 169. Started Feb 2011; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-023349-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023349-32.